Neurocognitive Impairment and HIV Risk Factors: a Reciprocal Relationship

Overview

Journal AIDS Behav

Specialty Infectious Diseases

Date 2010 Mar 17

PMID 20232242

Citations 84

Authors

Pria Anand

Sandra A Springer

Michael M Copenhaver

Frederick L Altice

Affiliations

Soon will be listed here.

Abstract

Cognitive impairment among populations at risk for HIV poses a significant barrier to managing risk behaviors. The impact of HIV and several cofactors, including substance abuse and mental illness, on cognitive function is discussed in the context of HIV risk behaviors, medication adherence, and risk-reduction interventions. Literature suggests that cognitive impairment is intertwined in a close, reciprocal relationship with both risk behaviors and medication adherence. Not only do increased risk behaviors and suboptimal adherence exacerbate cognitive impairment, but cognitive impairment also reduces the effectiveness of interventions aimed at optimizing medication adherence and reducing risk. In order to be effective, risk-reduction interventions must therefore take into account the impact of cognitive impairment on learning and behavior.

Citing Articles

Predicting antiretroviral medication adherence among substance-using people with HIV: test and extension of the information-motivation-behavioral skills model.

Krishnan A, Ranjit Y, Zhou X, Altice F J Behav Med. 2025; .

PMID: 39924604 DOI: 10.1007/s10865-025-00557-y.

Efficacy of aerobic exercise for HIV-associated neurocognitive disorders receiving ART: An RCT.

Nweke M, Mshunqane N S Afr J Physiother. 2025; 80(1):2104.

PMID: 39822344 PMC: 11736550. DOI: 10.4102/sajp.v80i1.2104.

Patient-oriented unsupervised learning to uncover the patterns of multimorbidity associated with stroke using primary care electronic health records.

Delord M, Sun X, Learoyd A, Curcin V, Wolfe C, Ashworth M BMC Prim Care. 2024; 25(1):419.

PMID: 39702052 PMC: 11656854. DOI: 10.1186/s12875-024-02636-6.

Occurrence of Opioid-Related Neurocognitive Symptoms Associated With Long-term Opioid Therapy.

Leon C, Sung M, Reisman J, Liu W, Kerns R, Gordon K Clin J Pain. 2024; 41(2).

PMID: 39682036 PMC: 11729567. DOI: 10.1097/AJP.0000000000001266.

Effects of Alcohol Use on Patient Retention in HIV Care in East Africa.

Monroy A, Goodrich S, Brown S, Balanos T, Bakoyannis G, Diero L AIDS Behav. 2024; 28(12):4020-4028.

PMID: 39225889 PMC: 11586299. DOI: 10.1007/s10461-024-04483-z.

References

Wexler B, Anderson M, Fulbright R, Gore J . Preliminary evidence of improved verbal working memory performance and normalization of task-related frontal lobe activation in schizophrenia following cognitive exercises. Am J Psychiatry. 2000; 157(10):1694-7. DOI: 10.1176/appi.ajp.157.10.1694. View

Avants S, Margolin A, Usubiaga M, Doebrick C . Targeting HIV-related outcomes with intravenous drug users maintained on methadone: a randomized clinical trial of a harm reduction group therapy. J Subst Abuse Treat. 2004; 26(2):67-78. DOI: 10.1016/S0740-5472(03)00159-4. View

Kalichman S . Co-occurrence of treatment nonadherence and continued HIV transmission risk behaviors: implications for positive prevention interventions. Psychosom Med. 2008; 70(5):593-7. DOI: 10.1097/PSY.0b013e3181773bce. View

Lovejoy T, Suhr J . The relationship between neuropsychological functioning and HAART adherence in HIV-positive adults: a systematic review. J Behav Med. 2009; 32(5):389-405. DOI: 10.1007/s10865-009-9212-9. View

Blume A, Marlatt G . The role of executive cognitive functions in changing substance use: what we know and what we need to know. Ann Behav Med. 2009; 37(2):117-25. DOI: 10.1007/s12160-009-9093-8. View

Woods S, Moore D, Weber E, Grant I . Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev. 2009; 19(2):152-68. PMC: 2690857. DOI: 10.1007/s11065-009-9102-5. View

de Castro S, Sabate E . Adherence to heroin dependence therapies and human immunodeficiency virus/acquired immunodeficiency syndrome infection rates among drug abusers. Clin Infect Dis. 2003; 37 Suppl 5:S464-7. DOI: 10.1086/377561. View

McCutchan J, Wu J, Robertson K, Koletar S, Ellis R, Cohn S . HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients. AIDS. 2007; 21(9):1109-17. DOI: 10.1097/QAD.0b013e3280ef6acd. View

Morgenstern J, Bates M . Effects of executive function impairment on change processes and substance use outcomes in 12-step treatment. J Stud Alcohol. 1999; 60(6):846-55. DOI: 10.15288/jsa.1999.60.846. View

10.

Copenhaver M, Avants S, Warburton L, Margolin A . Intervening effectively with drug abusers infected with HIV: taking into account the potential for cognitive impairment. J Psychoactive Drugs. 2003; 35(2):209-18. DOI: 10.1080/02791072.2003.10400002. View

11.

Simon S, Domier C, Sim T, Richardson K, Rawson R, Ling W . Cognitive performance of current methamphetamine and cocaine abusers. J Addict Dis. 2002; 21(1):61-74. DOI: 10.1300/j069v21n01_06. View

12.

Blume A, Davis J, Schmaling K . Neurocognitive dysfunction in dually-diagnosed patients: a potential roadblock to motivating behavior change. J Psychoactive Drugs. 1999; 31(2):111-5. DOI: 10.1080/02791072.1999.10471732. View

13.

Teplin L, Elkington K, McClelland G, Abram K, Mericle A, Washburn J . Major mental disorders, substance use disorders, comorbidity, and HIV-AIDS risk behaviors in juvenile detainees. Psychiatr Serv. 2005; 56(7):823-8. PMC: 1557408. DOI: 10.1176/appi.ps.56.7.823. View

14.

Douglas I, Smeeth L . Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ. 2008; 337:a1227. PMC: 2526549. DOI: 10.1136/bmj.a1227. View

15.

Rapeli P, Fabritius C, Alho H, Salaspuro M, Wahlbeck K, Kalska H . Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls. BMC Clin Pharmacol. 2007; 7:5. PMC: 1914339. DOI: 10.1186/1472-6904-7-5. View

16.

Pachet A, Wisniewski A . The effects of lithium on cognition: an updated review. Psychopharmacology (Berl). 2003; 170(3):225-234. DOI: 10.1007/s00213-003-1592-x. View

17.

Cook C, Hallwood P, Thomson A . B Vitamin deficiency and neuropsychiatric syndromes in alcohol misuse. Alcohol Alcohol. 1998; 33(4):317-36. DOI: 10.1093/oxfordjournals.alcalc.a008400. View

18.

Li W, Galey D, Mattson M, Nath A . Molecular and cellular mechanisms of neuronal cell death in HIV dementia. Neurotox Res. 2005; 8(1-2):119-34. DOI: 10.1007/BF03033824. View

19.

Gonzalez R, Vassileva J, Bechara A, Grbesic S, Sworowski L, Novak R . The influence of executive functions, sensation seeking, and HIV serostatus on the risky sexual practices of substance-dependent individuals. J Int Neuropsychol Soc. 2005; 11(2):121-31. DOI: 10.1017/s1355617705050186. View

20.

Di Franco M, Marlink R, Hunter D, Tosteson T, Mayer K, Essex M . Association of immune activation with intravenous heroin use and methadone treatment in HIV-1 seropositive and seronegative subjects. J Acquir Immune Defic Syndr (1988). 1993; 6(12):1297-300. View